Research programme: haemophilia therapeutics - Amunix/Bioverativ

Drug Profile

Research programme: haemophilia therapeutics - Amunix/Bioverativ

Alternative Names: BIVV 002; Blood coagulation factors recombinant - Amunix/Bioverativ; Factor IX recombinant - Amunix/Bioverativ; Factor VIIa recombinant - Amunix/Bioverativ; FIXFc-XTEN; rFIXFc-XTEN

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amunix; Biogen Idec
  • Developer Amunix; Bioverativ
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia B

Most Recent Events

  • 10 May 2018 Eagle Biologics has patent protection for formulation technology in USA
  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 22 Feb 2017 Swedish Orphan Biovitrum exercises its option to add candidate, rFIXFc XTEN to the company’s collaboration agreement with Bioverativ
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top